Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017.
capsular serotypes
resistance determinants
surface protein distributions
β-lactam nonsusceptibility
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
11
10
2019
accepted:
13
02
2020
pubmed:
16
2
2020
medline:
29
4
2021
entrez:
16
2
2020
Statut:
ppublish
Résumé
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of invasive infections in pregnant and nonpregnant adults. Vaccines targeting capsule polysaccharides and common proteins are under development. Using whole genome sequencing, a validated bioinformatics pipeline, and targeted antimicrobial susceptibility testing, we characterized 6340 invasive GBS isolates recovered during 2015-2017 through population-based Active Bacterial Core surveillance (ABCs) in 8 states. Six serotypes accounted for 98.4% of isolates (21.8% Ia, 17.6% V, 17.1% II, 15.6% III, 14.5% Ib, 11.8% IV). Most (94.2%) isolates were in 11 clonal complexes (CCs) comprised of multilocus sequence types identical or closely related to sequence types 1, 8, 12, 17, 19, 22, 23, 28, 88, 452, and 459. Fifty-four isolates (0.87%) had point mutations within pbp2x associated with nonsusceptibility to 1 or more β-lactam antibiotics. Genes conferring resistance to macrolides and/or lincosamides were found in 56% of isolates; 85.2% of isolates had tetracycline resistance genes. Two isolates carrying vanG were vancomycin nonsusceptible (minimum inhibitory concentration = 2 µg/mL). Nearly all isolates possessed capsule genes, 1-2 of the 3 main pilus gene clusters, and 1 of 4 homologous alpha/Rib family determinants. Presence of the hvgA virulence gene was primarily restricted to serotype III/CC17 isolates (465 isolates), but 8 exceptions (7 IV/CC452 and 1 IV/CC17) were observed. This first comprehensive, population-based quantitation of strain features in the United States suggests that current vaccine candidates should have good coverage. The β-lactams remain appropriate for first-line treatment and prophylaxis, but emergence of nonsusceptibility warrants ongoing monitoring.
Sections du résumé
BACKGROUND
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of invasive infections in pregnant and nonpregnant adults. Vaccines targeting capsule polysaccharides and common proteins are under development.
METHODS
Using whole genome sequencing, a validated bioinformatics pipeline, and targeted antimicrobial susceptibility testing, we characterized 6340 invasive GBS isolates recovered during 2015-2017 through population-based Active Bacterial Core surveillance (ABCs) in 8 states.
RESULTS
Six serotypes accounted for 98.4% of isolates (21.8% Ia, 17.6% V, 17.1% II, 15.6% III, 14.5% Ib, 11.8% IV). Most (94.2%) isolates were in 11 clonal complexes (CCs) comprised of multilocus sequence types identical or closely related to sequence types 1, 8, 12, 17, 19, 22, 23, 28, 88, 452, and 459. Fifty-four isolates (0.87%) had point mutations within pbp2x associated with nonsusceptibility to 1 or more β-lactam antibiotics. Genes conferring resistance to macrolides and/or lincosamides were found in 56% of isolates; 85.2% of isolates had tetracycline resistance genes. Two isolates carrying vanG were vancomycin nonsusceptible (minimum inhibitory concentration = 2 µg/mL). Nearly all isolates possessed capsule genes, 1-2 of the 3 main pilus gene clusters, and 1 of 4 homologous alpha/Rib family determinants. Presence of the hvgA virulence gene was primarily restricted to serotype III/CC17 isolates (465 isolates), but 8 exceptions (7 IV/CC452 and 1 IV/CC17) were observed.
CONCLUSIONS
This first comprehensive, population-based quantitation of strain features in the United States suggests that current vaccine candidates should have good coverage. The β-lactams remain appropriate for first-line treatment and prophylaxis, but emergence of nonsusceptibility warrants ongoing monitoring.
Identifiants
pubmed: 32060499
pii: 5736375
doi: 10.1093/cid/ciaa151
pmc: PMC8071603
mid: NIHMS1604968
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1004-1013Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
Emerg Infect Dis. 2013 Apr;19(4):551-8
pubmed: 23628320
Infect Immun. 1996 Sep;64(9):3518-23
pubmed: 8751893
J Infect Dis. 2009 May 15;199(10):1479-87
pubmed: 19392623
JAMA Intern Med. 2019 Apr 1;179(4):479-488
pubmed: 30776079
Antimicrob Agents Chemother. 2008 Aug;52(8):2915-8
pubmed: 18541727
Epidemiol Infect. 2011 Feb;139(2):236-8
pubmed: 20525412
Mol Microbiol. 2006 Jul;61(1):126-41
pubmed: 16824100
Clin Vaccine Immunol. 2015 Feb;22(2):153-9
pubmed: 25540270
JAMA Pediatr. 2019 Mar 1;173(3):224-233
pubmed: 30640366
PLoS One. 2015 Mar 17;10(3):e0120035
pubmed: 25781346
Antimicrob Agents Chemother. 2008 Aug;52(8):2890-7
pubmed: 18490507
J Infect Dis. 2009 Jan 1;199(1):108-15
pubmed: 19086816
J Exp Med. 2010 Oct 25;207(11):2313-22
pubmed: 20956545
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10278-83
pubmed: 21593422
J Bacteriol. 2004 Mar;186(5):1518-30
pubmed: 14973027
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
Vaccine. 2013 Aug 28;31 Suppl 4:D20-6
pubmed: 23219695
Cell Host Microbe. 2007 Dec 13;2(6):427-34
pubmed: 18078694
Emerg Infect Dis. 2015 Apr;21(4):585-91
pubmed: 25811284
Infect Immun. 2005 May;73(5):3096-103
pubmed: 15845517
Emerg Infect Dis. 2015 Sep;21(9):1520-8
pubmed: 26292067
J Antimicrob Chemother. 2013 Jul;68(7):1533-6
pubmed: 23449828
Ann Lab Med. 2019 Jul;39(4):414-416
pubmed: 30809991
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30873933
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S160-S172
pubmed: 29117326
Emerg Microbes Infect. 2019;8(1):2-7
pubmed: 30866792
J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):304-8
pubmed: 26237371
Clin Microbiol Rev. 2018 Aug 15;31(4):
pubmed: 30111577
J Antimicrob Chemother. 2017 Jul 1;72(7):1886-1892
pubmed: 28333320
Vaccine. 2019 May 27;37(24):3190-3198
pubmed: 31031031
Clin Microbiol Infect. 2017 Aug;23(8):574.e7-574.e14
pubmed: 28257899
mBio. 2014 Jul 22;5(4):e01386-14
pubmed: 25053786
J Antimicrob Chemother. 2015;70(6):1601-3
pubmed: 25667406
Science. 2005 Jul 1;309(5731):148-50
pubmed: 15994562
J Infect Dis. 2019 Jun 5;220(1):105-115
pubmed: 30778554